ACS Chemical Neuroscience Molecule Spotlight on Telcagepant (MK-0974)

被引：3
|
作者：
Hopkins, Corey R. [1 ,2 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA
来源：
ACS CHEMICAL NEUROSCIENCE | 2011年 / 2卷 / 07期
关键词：
MIGRAINE; HEADACHE; EFFICACY;
D O I：
10.1021/cn200059f
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Telcagepant (MK-0974) is a novel calcitonin gene-related peptide (CGRP) receptor antagonise currently undergoing clinical trials for migraine (http://www.merck.com/research/pipeline/home.html). MK-0974 is currently being studied in phase III clinical trials.
引用
收藏
页码：334 / 335
页数：2
相关论文
共 50 条
  • [21] ACS Chemical Neuroscience Molecule Spotlight on Semagacestat (LY450139)
    Hopkins, Corey R.
    ACS CHEMICAL NEUROSCIENCE, 2010, 1 (08): : 533 - 534
  • [22] ACS Chemical Neuroscience Molecule Spotlight on Gilenya (Fingolimod; FTY720)
    Hopkins, Corey R.
    ACS CHEMICAL NEUROSCIENCE, 2011, 2 (03): : 116 - 117
  • [23] ACS Chemical Neuroscience Molecule Spotlight on Saphris (vol 1, pg 263, 2010)
    Hopkins, Corey R.
    ACS CHEMICAL NEUROSCIENCE, 2010, 1 (07): : 529 - 529
  • [24] ACS Chemical Neuroscience Molecule Spotlight on Latuda (Lurasidone; SM-13,496)
    Hopkins, Corey R.
    ACS CHEMICAL NEUROSCIENCE, 2011, 2 (02): : 58 - 59
  • [25] Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: Results from a randomized study in patients with migraine
    Depre, M.
    MacLeod, C.
    Palcza, J.
    Behm, M. O.
    de Lepeleire, I.
    Han, T.
    Panebianco, D.
    Smith, W. B.
    Blanchard, R.
    Chodakewitz, J. A.
    Murphy, M. G.
    de Hoon, J. N.
    CEPHALALGIA, 2013, 33 (16) : 1292 - 1301
  • [26] Comparison of the Vasoconstrictor Effects of the Calcitonin Gene-related Peptide Receptor Antagonist Telcagepant (MK-0974) and Zolmitriptan in Human Isolated Coronary Arteries
    Lynch, Joseph J., Jr.
    Regan, Christopher P.
    Edvinsson, Lars
    Hargreaves, Richard J.
    Kane, Stefanie A.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2010, 55 (05) : 518 - 521
  • [27] ACS Chemical Neuroscience Spotlight on CEP-1347
    Sweeney, Zachary K.
    Lewcock, Joseph W.
    ACS CHEMICAL NEUROSCIENCE, 2011, 2 (01): : 3 - 4
  • [28] Pharmacological profile of MK-0974, the first orally bioavailable CGRP receptor antagonist
    Kane, S. A.
    Salvatore, C. A.
    Hershey, J. C.
    Corcoran, H.
    Paone, D. V.
    Burgey, C. S.
    Williams, T. M.
    Graham, S. L.
    Vacca, J. P.
    Koblan, K. S.
    HEADACHE, 2007, 47 (05): : 812 - 812
  • [29] Challenges in the development of orally bioavailable antagonists of the calcitonin gene-related peptide receptor, a family B GPCR: Discovery of telcagepant (MK-0974) for the treatment of migraine
    Burgey, Chris
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237
  • [30] Effect of MK-0974, an oral CGRP antagonist, on the hemodynamic response to subligual nitroglycerin
    Van der Schueren, B. J.
    Blanchard, R.
    Murphy, M. G.
    Palcza, J.
    De Lepeleire, I.
    Van Hecken, A.
    Depre, M.
    de Hoon, J. N.
    HEADACHE, 2008, 48 : S63 - S64
12345